FDA OKs J&J unit's Remicade to treat children's ulcerative colitis

09/25/2011 | Family Practice News · Bloomberg

The FDA approved Remicade, or infliximab, for treating moderate to severe ulcerative colitis in patients ages 6 to 17 who do not respond adequately to conventional therapy. The tumor necrosis factor blocker includes a boxed warning about a risk of cancer and infection. Remicade, made by Johnson & Johnson unit Janssen Biotech, also treats Crohn's disease in children and adults as well as other inflammatory conditions in adults.

View Full Article in:

Family Practice News · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ